4 Undervalued Pharmaceuticals Stocks for Thursday, September 24
Discover the top 4 undervalued Pharmaceuticals stocks for Thursday, September 24 based on AAII’s Stock Grades.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Apnimed, Inc.’s (APMD) Stock Is Down 5.25%
As of Thursday, September 24, Apnimed, Inc.’s APMD share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Michael Rose
Why Apnimed, Inc.’s (APMD) Stock Is Down 8.08%
As of Wednesday, September 23, Apnimed, Inc.’s APMD share price has dipped by 8.08%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Apnimed, Inc.’s (APMD) Stock Is Down 5.42%
As of Tuesday, September 22, Apnimed, Inc.’s APMD share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Apnimed, Inc.’s (APMD) Stock Is Down 12.88%
As of Monday, September 21, Apnimed, Inc.’s APMD share price has dipped by 12.88%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | APMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $878.0 | $565.8 | 44% |
|
| Shares Out (Mil) | 32.4 | 42.5 | 38% |
|
| Institutional Ownership | 93.5% | 83.9% | 63% |
|
| Float (Mil) | 20.5 | 45.7 | 29% |
|
| Beta | na | 0.72 | na |
|
| Avg Daily Volume (000s) | 835 | 402 | 65% |
|
| Price Change (52-week) |
na | 61.7% | na |
|
| Growth | APMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 4 | |
| Current EPS | ($0.600) | ($0.060) | ($3.975) | |
| Month Ago EPS | ($0.397) | ($0.213) | ($4.018) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (115.3%) | (99.4%) | (73.7%) | |
| Financials | APMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $115 | $317 | 27% |
|
| Net Income (TTM) (Mil) | $164 | ($11) | 66% |
|
| EPS (TTM) | $30.192 | ($0.700) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | ($70) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $80 | $6 | 43% |
|
| Enterprise Value (Q1) (Mil) | $1,361 | $493 | 44% |
|
| Valuation | APMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.40 | na |
|
| P/E | 2.4 | 17.3 | 2% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | APMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.9% | 69.4% | 95% |
|
| Net Margin | 142.1% | 2.0% | 99% |
|
| ROA | 167.4% | (22.2%) | 100% |
|
| ROE | (185.7%) | (22.8%) | 4% |
|
| Liabilities to Assets | 64.3% | 32.5% | 59% |
|
| F-Score | 1 | 3 | na |
|
Apnimed, Inc. did not pass any screens on 9/25/2026.
